VBI Vaccines

China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from an interim analysis of a randomized, placebo-controlled, and double-blinded Phase II study of BRII-179 (VBI-2601), a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, used in combination with pegylated interferon-alpha (PEG-IFNα) for the treatment of chronic hepatitis B virus…